SC
CYTK icon

Shay Capital’s Cytokinetics CYTK Stock Holding History

Shay Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,275
Closed -$216K – 533
2026
Q1 		$216K Sell
3,275
-311
-9% -$19.8K 0.02% 379
2025
Q4 		$228K Sell
3,586
-2,429
-40% -$151K 0.02% 402
2025
Q3 		$331K Sell
6,015
-1,485
-20% -$61.2K 0.03% 299
2025
Q2 		$248K Buy
7,500
+2,449
+48% +$85.2K 0.03% 239
2025
Q1 		$203K Sell
5,051
-77
-2% -$3.54K 0.03% 240
2024
Q4 		$241K Hold
5,128
– – 0.04% 240
2024
Q3 		$271K Sell
5,128
-35
-0.7% -$1.95K 0.04% 228
2024
Q2 		$280K Sell
5,163
-16,179
-76% -$977K 0.04% 200
2024
Q1 		$1.5M Sell
21,342
-16,452
-44% -$1.27M 0.23% 74
2023
Q4 		$3.16M Buy
+37,794
New +$1.37M 0.63% 37

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shay Capital's CYTK Position: Q2 2026 in Review

Shay Capital sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 3,275 shares — an estimated $216K sold.

Shay Capital first reported a position in CYTK in Q4 2023 and held it in 10 quarters. The position peaked at $3.16M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Shay Capital reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Shay Capital sold 3,275 Cytokinetics shares in Q2 2026, an estimated $216K.
  • Shay Capital first reported a position in Cytokinetics in Q4 2023 and held it in 10 quarters.
  • Shay Capital's Cytokinetics position peaked at $3.16M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.